Table 1.
Baseline characteristics of 338 HCC patients
| Variables | Total cohort (n = 338) |
BCLC 0/A HCC (n = 205) |
BCLC B/C HCC (n = 133) |
|---|---|---|---|
| Age, years† | 52 (44–66) | 52 (44–60) | 52 (43–60) |
| Male gender‡ | 299 (88.5) | 180 (87.5) | 119 (89.5) |
| Positive HBsAg‡ | 278 (82.2) | 170 (82.9) | 108 (81.2) |
| Total bilirubin, μmol/l† | 14.0 (13.4–19.4) | 13.9 (10.0–19.6) | 14.4 (10.6–18.7) |
| Albumin, g/l† | 37.9 (35.1–40.8) | 38.0 (35.4–41.0) | 37.6 (34.0–40.7) |
| ALT, U/l† | 36.1 (25.8–52.0) | 34.3 (24.7–53.0) | 37.9 (26.4–51.0) |
| Prothrombin time, s† | 13.2 (12.0–14.1) | 13.2 (12.0–14.1) | 13.2 (12.1–14.1) |
| INR† | 1.04 (0.95–1.14) | 1.04 (0.94–1.14) | 1.05 (0.95–1.14) |
| Platelet count, × 109/l† | 155 (110–205) | 155 (110–211) | 154 (113.5–201.5) |
| Maximum tumor size, cm† | 6.0 (4.2–10.0) | 6.0 (3.5–9.2) | 8 (5.0–11.0) |
| Serum AFP, ng/ml‡ | |||
| ≥ 400 | 141 (41.7) | 73 (35.6) | 68 (51.1) |
| < 400 | 197 (58.3) | 132 (64.4) | 65 (48.9) |
| CSPH‡ | 56 (16.6) | 34 (16.6) | 22 (16.5) |
| ALBI score† | − 2.460 (− 2.704– − 2.192) | − 2.518 (− 2.719–− 2.236) | − 2.399 (− 2.702–− 2.136) |
| ALBI grade‡ | |||
| 1 | 134 (39.6) | 89 (43.4) | 45 (33.8) |
| 2 | 198 (58.6) | 114 (55.6) | 84 (63.2) |
| 3 | 6 (1.8) | 2 (1.0) | 4 (3.0) |
| MELD score (range) | 7 (6–18) | 7 (6–18) | 7 (6–17) |
| MELD score‡ | |||
| ≥ 9 | 88 (26.0) | 47 (22.9) | 41 (30.8) |
| < 9 | 250 (74.0) | 158 (77.1) | 92 (69.2) |
| Child-Pugh grade‡ | |||
| A | 308 (91.1) | 190 (92.7) | 118 (88.7) |
| B | 30 (8.9) | 15 (7.3) | 15 (11.3) |
| C | 0 (0) | 0 (0) | 0 (0) |
| BCLC stage‡ | |||
| 0 | 12 (3.6) | – | – |
| A | 193 (57.1) | – | – |
| B | 82 (24.3) | – | – |
| C | 51 (15.1) | – | – |
HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, ALT alanine aminotransferase, INR international normalized ratio, AFP α-fetoprotein, CSPH clinically significant portal pressure, ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer
†Values are median (interquartile range)
‡Values are number (%)